Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Can The UK Remain A First Launch Market?

Uncertainty, Modifiers and Discounts Key To NICE Methods Update

Executive Summary

More political support from the National Health Service and health ministers is needed to ensure the UK’s future as a desirable launch market.

You may also be interested in...



UK MHRA Aims To Cast Early Access Scheme In New Light

The UK’s Early Access to Medicines Scheme continues to provide important flexibility, but companies also now have the option of a new ambitious pathway launched this year for accelerating time to market for innovative medicines.

Global Boardrooms Sceptical About Potential For UK To Be Lifesciences Superpower

The UK has the potential to fulfill its ambition of being a global superpower in life sciences, but it must not get lost in an echo chamber, says a senior MSD executive.

UK Spinraza Data Review Shows Benefits Of NICE Flexibility

Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.

Related Content

Topics

UsernamePublicRestriction

Register

PS144111

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel